Contact
Please use this form to send email to PR contact of this press release:
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
TO: